Eosinophil-mediated cellular cytotoxicity induced by zymosan-activated serum.
The aim of the present work was to develop an in vitro model of eosinophil cytotoxicity which mimics numerous in vivo situations characterized by complement activation through the alternative pathway. Our results demonstrate that eosinophilic granulocytes from patients with parasitic diseases and blood eosinophilia were able to damage chicken red blood cells when incubated with zymosan-activated serum (ZAS) as assessed by a 51Cr release assay. The phenomenon was independent of the presence of antibodies directed against the target cells and related to the quantity of ZAS added to the wells. As target cell lysis is totally or partially inhibited by catalase, sodium azide and potassium cyanide, an involvement of toxic oxygen derivatives as cytolytic mediators was suggested.
D001386:Azides / Q000494:pharmacology; D001798:Blood Proteins / Q000276:immunology*; D002374:Catalase / Q000494:pharmacology; D002860:Chromium Radioisotopes; D003182:Complement C5 / Q000097:blood; D015936:Complement C5a; D003170:Complement Pathway, Alternative / Q000187:drug effects; D003602:Cytotoxicity, Immunologic; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D010272:Parasitic Diseases / Q000473:pathology; D011190:Potassium Cyanide / Q000494:pharmacology; D019810:Sodium Azide; D013482:Superoxide Dismutase / Q000494:pharmacology; D015054:Zymosan / Q000276:immunology* / Q000494:pharmacology
D001386:Azides; D001798:Blood Proteins; D002860:Chromium Radioisotopes; D003182:Complement C5; D015936:Complement C5a; D015054:Zymosan; D019810:Sodium Azide; D002374:Catalase; D013482:Superoxide Dismutase; D011190:Potassium Cyanide